Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab for measurable residual disease in t(8;21) acute myeloid leukemia
ISRCTN52962455Phase 4Completed
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Nov 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 4 trial of blinatumomab, sponsored by Guy's and St Thomas' NHS Foundation Trust. Started Nov 2021; status: completed.
02
Drugs
blinatumomab
Beyond the preview
Go deeper on ISRCTN52962455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN52962455.